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Abstract
Background: Little information is available on resistance to anti-malarial drugs in the Solomon Islands (SI). The
analysis of single nucleotide polymorphisms (SNPs) in drug resistance associated parasite genes is a potential
alternative to classical time- and resource-consuming in vivo studies to monitor drug resistance. Mutations in
pfmdr1 and pfcrt were shown to indicate chloroquine (CQ) resistance, mutations in pfdhfr and pfdhps indicate
sulphadoxine-pyrimethamine (SP) resistance, and mutations in pfATPase6 indicate resistance to artemisinin
derivatives.
Methods: The relationship between the rate of treatment failure among 25 symptomatic Plasmodium falciparum-
infected patients presenting at the clinic and the pattern of resistance-associated SNPs in P. falciparum infecting 76
asymptomatic individuals from the surrounding population was investigated. The study was conducted in the SI in
2004. Patients presenting at a local clinic with microscopically confirmed P. falciparum malaria were recruited and
treated with CQ+SP. Rates of treatment failure were estimated during a 28-day follow-up period. In parallel, a DNA
microarray technology was used to analyse mutations associated with CQ, SP, and artemisinin derivative resistance
among samples from the asymptomatic community. Mutation and haplotype frequencies were determined, as well
as the multiplicity of infection.
Results: The in vivo study showed an efficacy of 88% for CQ+SP to treat P. falciparum infections. DNA microarray
analyses indicated a low diversity in the parasite population with one major haplotype present in 98.7% of the
cases. It was composed of fixed mutations at position 86 in pfmdr1, positions 72, 75, 76, 220, 326 and 356 in pfcrt,
and positions 59 and 108 in pfdhfr. No mutation was observed in pfdhps or in pfATPase6. The mean multiplicity of
infection was 1.39.
Conclusion: This work provides the first insight into drug resistance markers of P. falciparum in the SI. The
obtained results indicated the presence of a very homogenous P. falciparum population circulating in the
community. Although CQ+SP could still clear most infections, seven fixed mutations associated with CQ resistance
and two fixed mutations related to SP resistance were observed. Whether the absence of mutations in pfATPase6
indicates the efficacy of artemisinin derivatives remains to be proven.
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Background
Shrinking the malaria map is now proposed as a realistic
goal in many countries [1,2]. The Solomon Islands (SI)
are one of the so defined “elimination countries”. Being
an insular nation with varying levels of endemicity and
transmission on most populated islands [3], and located
at the margins of the endemic zones makes it feasible to
embark upon malaria elimination. However, to reach
this target, it is of crucial importance to gather informa-
tion about the local malaria epidemiology. Limited infor-
mation is available on the prevalence of mutations
associated with drug resistance or on the population
structure of malaria parasites in the SI. The present
study provides baseline data on Plasmodium falciparum
malaria gathered in the Guadalcanal Province in 2004,
with focus on anti-malarial resistance.
In vivo studies are still considered the gold standard
for the assessment of anti-malarial drug efficacy. The
analysis of parasite molecular markers has been pro-
posed as an alternative approach for the estimation of
resistance to treatment. It has been shown that chloro-
quine (CQ) resistance is associated with mutations in
pfmdr1 (P. falciparum multidrug resistance gene, coding
for P-glycoprotein homologue-1, pgh1) and pfcrt (P. fal-
ciparum chloroquine resistance transporter gene) [4-9].
Similarly, it is known that sulphadoxine-pyrimethamine
(SP) resistance is associated with mutations in the genes
pfdhfr (dihydrofolate reductase) and pfdhps (dihydrop-
teroate synthase) [10-14]. Mutations in pfATPase6 have
been described as potential molecular markers involved
in resistance to artemisinin derivatives [15]. However,
solid evidence for their association with artemisinin
resistance is lacking to date.
The analysis of such parasite mutations has the advan-
tage over classical in vivo studies that it can be con-
ducted on samples collected on the first day of health
centre attendance. It is therefore independent of compli-
ance and circumvents the need for time- and resource-
consuming follow-up, which often leads to significant
patient loss.
Most of the previous studies on parasite mutations
were based on samples obtained from patients prior to
treatment. However, there is evidence that the molecular
profile of parasites circulating in the community
matches the one observed among patients attending
health centres. Talisuna et al [16] showed that the pre-
sence of pfdhfr mutations in the community was inde-
pendently correlated with the clinical treatment
outcome. Therefore, not only symptomatic patients, but
also asymptomatic individuals could be used to establish
the prevalence of single nucleotide polymorphisms
(SNPs) in the parasite population [17].
The classical molecular techniques are based on indi-
vidual examination of SNPs by restriction fragment
length polymorphism (RFLP) analysis, allele-specific
amplification or DNA sequencing. Unfortunately, these
methods are labour-intensive if performed on many
SNPs, especially for the analysis of large sample sizes.
The analysis of multiple SNPs has been shown to allow
a better prediction of the clinical outcome compared to
the evaluation of individual SNPs. This argued for a
technique facilitating parallel typing of multiple SNPs
[9,18-24]. To enable high throughput analysis of several
point mutations, a sensitive and rapid SNP typing tech-
nique based on DNA microarray was used for the
simultaneous assessment of all known resistance-
associated SNPs located in genes pfcrt, pfmdr1, pfdhfr,
pfdhps and pfATPase6 [25].
Prior to this study, the malaria drug resistance micro-
array was validated with field studies conducted in dif-
ferent epidemiological and geographical settings,
including Papua New Guinea (PNG) [17,24], and Tanza-
nia. The relationship between SNP prevalence in sam-
ples collected in the asymptomatic community and the
rate of treatment failure derived from clinical in vivo
studies was investigated. In PNG, two investigated sites
had different rates of treatment failure, which were
reflected by different patterns of resistance markers in
the corresponding parasite populations [17]. In the
frame of that multisite study, the present work reports
on an additional field study conducted in 2004 at the
north of Guadalcanal province in the SI.
A classical in vivo study was conducted to assess the
level of CQ+SP failure among symptomatic P. falci-
parum malaria patients. In parallel, a cross-sectional
survey in the surrounding asymptomatic community
allowed the assessment of SNP prevalence. After the
completion of this study, the SI Ministry of Health mod-
ified the national treatment guidelines for P. falciparum
infections. Since 2008, standard first-line treatment for
P. falciparum malaria has been changed to the combina-
tion of artemether plus lumefantrine.
Methods
Study area
The study was conducted in Tetere area, Guadalcanal
Province of SI between November 2004 and May 2005,
roughly corresponding to the rainy season. The SI are
located northeast of Australia, at a latitude of 8° South
and a longitude of 159° East. The drug efficacy in vivo
study was conducted at the Lunga clinic, located about
10 km east from Honiara, the capital city of the country.
The community-based cross-sectional survey was carried
out in 3 villages nearby, which are part of the Lunga
clinic catchment area. According to the prevalence of
malaria among children aged between 2 and 9 years, the
endemicity of P. falciparum and Plasmodium vivax
malaria in that area is considered mesoendemic.
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In vivo drug efficacy study
Procedures followed the World Health Organization
protocol for 28-day assessment of treatment efficacy for
uncomplicated P. falciparum malaria in areas of low to
moderate transmission [26]. Clinically manifest and
microscopically confirmed malaria patients visiting the
Lunga clinic were recruited if they were aged > 6
months, had an axillary temperature ≥ 37.5°C or history
of fever during the last 48 hours, a P. falciparum density
between 1,000 and 100,000 asexual parasites per micro-
litre blood, no signs of severe or complicated malaria
and no signs of any other disease. The patients received
the first dose of medicine on the day of enrolment (i.e.
day 0). Follow-up visits were scheduled on days 1, 2, 3,
7, 14, 21 and 28. Patients were advised to come to the
clinic on any other day if symptoms occurred. On every
visit, patients were clinically examined and blood sam-
ples were taken by finger prick, except on day 1. The
parasite density was assessed by microscopy after
Giemsa staining of blood slides. In case of a microscopi-
cally confirmed P. falciparum infection on day 0, stan-
dard treatment, which at that time was CQ+SP, was
administered under supervision. CQ was given on days
0, 1 and 2 (10 mg/kg chloroquine phosphate per day)
and SP was given as a single dose on day 0 (25 mg/kg
sulphadoxine + 1.25 mg/kg pyrimethamine). Patients
failing first-line treatment were treated with quinine (10
mg/kg quinine sulphate, three times a day for three
days) plus a single dose of SP (25 mg/kg sulphadoxine +
1.25 mg/kg pyrimethamine, on the first day of second-
line treatment).
Community-based cross-sectional survey
Three villages within the catchment area of the clinic
have been selected for the community-based cross-sec-
tional survey. Clinical symptoms during the last seven
days, history of malaria and consumption of anti-malar-
ials were reported on an individual questionnaire. Axil-
lary temperature was taken with a digital thermometer
and blood samples were collected by finger prick. After
microscopy examination of the slides, P. falciparum
positive people were informed of the result and treated
with the first-line treatment at that time.
Molecular analyses
To distinguish a true recrudescence from a new infec-
tion (in vivo drug efficacy study), and to determine PCR
prevalence of P. falciparum infections and the multipli-
city of infection (MOI) in the community, paired in vivo
study and community survey samples were genotyped
by PCR-RFLP of P. falciparum msp2 (merozoite surface
protein 2) [27]. In brief, after DNA extraction (QIAamp®
DNA Blood Kit, Qiagen, Switzerland), the msp2 gene
was amplified by nested PCR and digested with
restriction enzymes Hinf I and Dde I. Restriction frag-
ment patterns were analysed after electrophoresis on
10% polyacrylamide gels.
Mutations associated with anti-malarial resistance
were assessed by microarray technology among P. falci-
parum positive samples as described in detail elsewhere
[25]. The method is based on the parallel PCR amplifi-
cations of the target sequences followed by primer
extension using fluorochrome-labelled ddNTPs. After
denaturation, primer extension products were specifi-
cally hybridized onto the microarray. All SNPs assessed
on the microarray are listed in Figure 1.
The data output given by the Axon GenePix™software
(Molecular Devices Inc., USA) was edited and converted
into a table listing all SNPs with their respective geno-
type (i.e., wild-type, mutated or mixed) for each patient.
For quality control of the SNP microarray typing, data
of some of the samples were confirmed by sequencing
(Macrogen Inc., Korea).
In vivo drug efficacy
According to the microscopic observation of patient
blood smears and after PCR correction by msp2 geno-
typing, the individual treatment outcomes were classified
according to the categories defined by WHO for low to
moderate transmission areas [26]: Early Treatment
Failure (ETF), Late Clinical Failure (LCF), Late Parasito-
logical Failure (LPF), and Adequate Clinical and Parasi-
tological Response (ACPR). The treatment failure rate
among P. falciparum malaria patients was calculated for
patients who successfully completed the study. The
overall treatment failure (TF) rate was obtained by pool-
ing ETF, LCF and LPF rates.
Ethical approval
The National Ethics Committee of the SI and the Basel
Ethic Commission (Ethikkommission beider Basel) in
Switzerland reviewed and approved the study protocol.
All communities and patients (or parents and legal guar-
dians) involved were enrolled in the study after having
given informed consent.
Results
The field procedures were conducted in 2004-2005 in
the North coast of Guadalcanal Province in the SI.
In vivo study
A total of 43 (100%) patients aged between 2 and 23
years (median: 9 years) completed the in vivo study. No
patient was lost to follow-up. 18 (41.9%) patients were
included without meeting the required criteria (i.e. they
were without fever (or history of fever) and/or had a
parasite density below 1,000 P. falciparum/μl on day 0).
These individuals were censored from further analysis.
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Among the 25 (58.1%) remaining patients the following
outcomes were observed after PCR correction: 22 (88%)
ACPR, 1 ETF (4%) and 2 LPF (8%), giving a total of 12%
TF.
Community-based cross-sectional survey
Three villages comprising the catchment area of the
Lunga clinic were screened for asymptomatic P. falci-
parum infected individuals. Due to very limited census
data from those three villages, the combined total popu-
lation could only be roughly estimated to 1600 inhabi-
tants. A total of 388 asymptomatic individuals (24.3% of
the estimated total population) aged between 1 and 73
years (median: 17 years) were screened in the commu-
nity, among them 53.4% females. Based on microscopy
reading of blood smears, 50/388 (12.9%) individuals
were infected with P. falciparum; using msp2 PCR, 97/
388 individuals were found positive, giving a prevalence
rate of 25% P. falciparum malaria.
RFLP analysis was successfully conducted on 80 sam-
ples. The msp2 PCR fragment revealed 56 (70%) single
infections, 18 (22.5%) double infections, five (6.25%) tri-
ple infections and one (1.25%) quadruple infection. The
mean multiplicity of infection (MOI; mean number of
co-infecting parasite clones) in P. falciparum positive
samples was 1.39.
Ten PCR reactions were performed for the five genes
associated with drug resistance. Of the 97 P. falciparum
positive samples analysed, 21 (21.6%) showed poor
amplification for the majority of the PCR reactions (> 5
poor PCR results out of 10) and had thus to be
excluded. The 76 (78.4%) remaining samples were used
for genotyping by microarray. Sixteen unclear microar-
ray typing outcomes were confirmed by sequencing of
the corresponding gene fragments (Macrogen Inc.,
Korea).
Overall, the analysed population showed to be very
homogenous (Figure 2). Two different haplotypes were
observed for the two CQ resistance-associated genes.
With 70% of the patients having a single infection and
the unambiguous DNA microarray signals, it was con-
sidered that co-infecting clones had the same pattern of
SNPs. The most dominant haplotype showed mutations
at positions pfmdr1 N86Y and pfcrt C72 S, N75D/E,
K76T, A220 S, N326 D, and I356L, and was observed in
98.4% (61/62) of the population. The second haplotype
was observed in one sample only (1.6%) and differed
from the first one by having one additional mutation at
position N1042 D in pfmdr1. Other SNPs related to CQ
resistance were all wild-type.
For the genes involved in SP resistance, mutations
were fixed at positions C59R and S108N in pfdhfr.
Other SNPs in pfdhfr and pfdhps were all wild-type. No
mutation was detected in pfATPase6.
Discussion
The outcome of CQ+SP against falciparum malaria was
investigated at a clinic located close to Honiara in the
SI. At the same time, the presence of resistance-asso-
ciated SNPs in P. falciparum was assessed in the
surrounding asymptomatic community, screened by a
cross-sectional survey.
The resistance-associated SNPs observed in the sam-
ple set are in line with previous findings from other
malaria areas worldwide. Regarding SP resistance, all
samples presented two fixed mutations at positions
C59R and S108N in pfdhfr and none in pfdhps. The
importance of cumulative mutations conferring SP resis-
tance has been described; in particular the combination
of the SNPs pfdhfr S108N, N51I, C59R and pfdhps
A437G, K540E [9,28] being correlated with anti-folate
treatment failure. The double mutant pfdhfr C59R
Figure 1 List of the 34 anti-malarial resistance SNPs assayed on the DNA microarray. CQ resistance-related markers included 5 SNPs
located in pfmdr1 and 13 SNPs located in pfcrt. SP resistance-related markers included 6 SNPs located in pfdhfr and 6 SNPs located in pfdhps.
Putative artemisinin-resistance related markers included 4 SNPs located in pfATPase6.
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+S108N, previously shown to be associated with treat-
ment failure [23], has been reported at high prevalence
in the SI and other Melanesian countries before
[11,29,30]. Regarding CQ resistance, fixed mutations at
positions pfcrt C72 S, N75D/E, K76T, A220 S, N326 D,
I356L and pfmdr1 N86Y were observed. The crucial role
of pfcrt K76T in conferring CQ resistance is well
known, together with additional mutations in pfcrt
maintaining functional properties [5,31]. The mutation
pfmdr1 N86Y is considered as a modulator of CQ resis-
tance in the presence of pfcrt mutations [32-34].
The present study was part of a multisite project simul-
taneously conducted in Tanzania (Mugittu et al, unpub-
lished) and PNG [17,24]. In this context, it is interesting to
compare the observations from the SI with reports from
PNG due to the close location of both countries (PNG is
situated about 1500 km West of Honiara) and the com-
mon origin of the mainly Melanesian human population.
The SNPs seen in PNG community samples in 2003-2005
reflected the SI observations with high mutation frequen-
cies in pfcrt and pfmdr1, moderate mutation frequencies
in pfdhfr, and rare mutations in pfdhps [24]. Also similar
to the SI, the mutation pfmdr1 N1042 D was only seen in
1% of the PNG patients. Mutations in pfATPase6 were
neither observed in the SI, nor in PNG. The observation
of pfATPase6 mutations in French Guiana has so far not
been confirmed elsewhere [35,36].
Due to the small sample size, conclusions on the cor-
relation between the prevalence of molecular markers in
the parasite population infecting the community and the
in vivo treatment failure rate cannot be drawn. The in
vivo study conducted at the clinic showed 12% of CQ
+SP failure, which can partially be explained by the fixa-
tion of the SP resistance-conferring pfdhfr C59R+S108N
double mutant in the parasite population. However,
PNG data showed that not all mutations predict treat-
ment failure at the same level [24]: mutations pfmdr1
N86Y and pfdhps A437G were the strongest predictors
of amodiaquine+SP failure. It can be postulated that the
absence of the pfdhps A437G mutation explains the
lower rate of treatment failures in the SI compared to
PNG and indicates that SP, and even more specifically
sulphadoxine, might have been the effective component
of the drug combination. The poor efficacy of CQ has
indeed already been reported in the 1980’s, when CQ
monotherapy was used (Bobogare et al., unpublished
data). The combination of CQ+SP used in the 1990 s as
second-line treatment, and subsequently as first-line
treatment between 2003 and 2007, certainly further
maintained a CQ pressure and thus its limited efficacy.
The use of DNA microarray allowing the parallel ana-
lysis of antimalaria drug resistance markers was particu-
larly advantageous in the context of CQ+SP as first line
treatment, since many polymorphisms have been
Figure 2 Observed haplotypes of SNPs related to resistance to CQ, SP and artemisinin derivatives. A haplotype is defined by the
combination of mutations in genes related to drug resistance. Grey indicates mutations and white indicates wild-type. Two different haplotypes
were observed in genes pfmdr1 and pfcrt. One haplotype was observed in genes pfdhfr and pfdhps. One haplotype was observed in gene
pfATPase6. n corresponds to the number of samples assessed for the analysis.
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described for those two drugs. In contrast, no marker is
validated as indicators of artemether plus lumefantrine
combination therapy, which has replaced CQ+SP in the
SI since 2008. The determination of the pfmdr1 copy
number in samples collected after 2008 could provide a
useful complement for the assessment of potential resis-
tance to artemether and lumefantrine.
The observed low genetic diversity of the P. falci-
parum population does probably reflect the context of
an island country, where gene flow may be restricted.
This low diversity was compared with observations in
PNG [24]. In contrast to the SI situation, where muta-
tions associated with antimalarial drug resistance tended
to be fixed, the diversity was higher in PNG with various
SNP patterns present in the P. falciparum population.
However, the most dominant SNP pattern related to
CQ resistance seen in PNG between 1992 and 2002 [37]
was composed of mutations pfcrt K76T, A220 S, N326
D and I356L, which corresponds to the dominant haplo-
type observed in the SI. Regarding SP resistance, the
dominant SNP pattern in PNG was the pfdhfr C59R
+S108N double mutant, which also corresponds to the
dominant haplotype in SI.
Parasite populations in SI and PNG show similarities
that can be explained by their close geographical vici-
nity. However, the pronounced insularity and remote-
ness of the SI differs from PNG and this may be
reflected in the lower genetic diversity observed in the
SI. The absence of mutations in pfdhps in the SI, which
are already present in PNG, is a possible illustration of
such low gene flow. A meta-population analysis on the
diversity of genes encoding P. falciparum vaccine anti-
gens also reported that biogeographic characteristics of
island nations in the Pacific constitute a barrier to gene
flow [38]. Restricted gene flow is also reflected in the
low mean multiplicity of infection in the SI (1.39 con-
current infections in parasite positive samples). For
comparison, in a coastal location in PNG having similar
geographical characteristics, the multiplicity of infection
was slightly higher (1.54), and the msp2 PCR-based P.
falciparum prevalence was also higher than in the SI
(32% versus 25%, respectively) [39].
An additional explanation for limited diversity in the
considered study site could be the vector control mea-
sures. Field evaluations have shown that insecticide-
impregnated bed nets and indoor residual spraying
together with educational activities significantly reduced
malaria transmission in north Guadalcanal Province and
contributed to a slow decrease of malaria incidence in
the SI since 1992 [40].
To further validate the hypothesis of restricted gene
flow in the SI in contrast to PNG, the diversity of var-
ious microsatellites which are not under selection pres-
sure could be tested.
In conclusion, the present data provide baseline infor-
mation on the prevalence of P. falciparum drug resis-
tance-associated SNPs and highlight the low level of
genetic diversity in the P. falciparum population in the
Guadalcanal Province of the SI. Surveillance of molecu-
lar markers of drug resistance should be an integral part
of the planned malaria eradication programmes, which
are currently initiated in insular settings, so that the
resistance dynamics can be assessed and the most effec-
tive treatment selected.
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